UNITED THERAPEUTICS Corp - Common Stock (UTHR)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
UTHR on Nasdaq
Shares outstanding
44,798,018
Price per share
$487.25
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
40,875,734
Holdings value
$17,137,629,356
% of all portfolios
0.02%
Share change
-2,995,478
Value change
-$1,069,670,491
Average buys %
+0.01%
Average sells %
-0.01%
Number of holders
694
Price from insider filings
$510.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of UNITED THERAPEUTICS Corp - Common Stock (UTHR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
STATE STREET CORP 4.9% $644,114,243 2,199,994 STATE STREET CORPORATION 31 Dec 2024
WELLINGTON MANAGEMENT GROUP LLP 4.5% -17% $593,294,076 -$128,083,930 2,026,416 -18% Wellington Management Group LLP 31 Mar 2025
As of 30 Sep 2025, UNITED THERAPEUTICS Corp - Common Stock (UTHR) has 694 institutional shareholders filing 13F forms. They hold 40,875,734 shares of 44,798,018 outstanding shares (91%) .

Top 25 institutional shareholders own 61% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 12% 5,352,996 +0.36% 0.04% $2,244,029,549
VANGUARD GROUP INC 9.9% 4,418,610 -0.68% 0.03% $1,852,325,498
RENAISSANCE TECHNOLOGIES LLC 4.9% 2,173,392 +2.6% 1.2% $911,107,660
Avoro Capital Advisors LLC 4.5% 2,022,222 -15% 11% $847,735,685
STATE STREET CORP 4.3% 1,922,609 -11% 0.03% $805,976,919
WELLINGTON MANAGEMENT GROUP LLP 3.1% 1,398,781 -3.1% 0.1% $586,382,984
GEODE CAPITAL MANAGEMENT, LLC 2.8% 1,249,660 +4.1% 0.03% $522,908,608
AQR CAPITAL MANAGEMENT LLC 2.2% 986,478 -23% 0.27% $413,541,523
Darwin Global Management, Ltd. 1.7% 748,550 8.8% $317,617,251
LSV ASSET MANAGEMENT 1.5% 686,710 -21% 0.64% $287,876,000
ASSETMARK, INC 1.4% 645,908 -9.8% 0.58% $270,771,197
Invesco Ltd. 1.4% 637,223 -28% 0.04% $267,130,253
CITIGROUP INC 1.2% 551,470 +1197% 0.16% $231,181,739
DIMENSIONAL FUND ADVISORS LP 1.1% 512,816 -11% 0.05% $214,994,809
JANUS HENDERSON GROUP PLC 1% 454,718 +62% 0.09% $190,569,761
NORTHERN TRUST CORP 1% 447,018 -1.2% 0.02% $187,394,415
MORGAN STANLEY 0.98% 438,803 +10% 0.01% $183,951,225
DEERFIELD MANAGEMENT COMPANY, L.P. 0.95% 425,993 -21% 2.7% $178,580,526
Bank of New York Mellon Corp 0.78% 351,455 -3% 0.03% $147,333,387
Pacer Advisors, Inc. 0.76% 339,071 -33% 0.36% $142,141,954
Swedbank AB 0.73% 329,118 -0.45% 0.14% $137,969,558
Pictet Asset Management Holding SA 0.72% 321,495 +52% 0.13% $134,870,472
FULLER & THALER ASSET MANAGEMENT, INC. 0.7% 315,305 -19% 0.45% $132,178,929
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.7% 312,948 -6.8% 0.02% $131,190,931
PRICE T ROWE ASSOCIATES INC /MD/ 0.67% 300,931 +163% 0.01% $126,154,000

Institutional Holders of UNITED THERAPEUTICS Corp - Common Stock (UTHR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 104,726 $51,420,603 +$14,608,860 $487.25 21
2025 Q3 40,875,734 $17,137,629,356 -$1,069,670,491 $419.21 694
2025 Q2 43,924,520 $12,621,621,981 -$132,393,669 $287.35 663
2025 Q1 44,378,846 $13,672,069,958 +$61,283,278 $308.27 659
2024 Q4 43,923,038 $15,501,991,244 +$187,675,652 $352.84 663
2024 Q3 43,091,175 $15,440,281,003 -$895,689,707 $358.35 617
2024 Q2 45,794,901 $14,582,299,264 +$483,642,559 $318.55 559
2024 Q1 44,668,215 $10,266,093,815 +$36,774,240 $229.72 517
2023 Q4 652,092 $143,343,779 +$8,235,029 $219.89 7
2023 Q3 43,524,236 $9,831,091,482 -$173,654,775 $225.87 496
2023 Q2 44,074,379 $9,727,755,731 -$249,429,682 $220.75 459
2023 Q1 44,647,136 $9,996,476,877 -$12,830,574 $223.96 491
2022 Q4 44,273,280 $12,309,140,520 +$52,941,634 $278.09 498
2022 Q3 43,465,728 $9,100,764,342 +$90,799,372 $209.38 436
2022 Q2 43,276,212 $10,167,776,291 +$121,668,106 $235.64 452
2022 Q1 43,386,665 $7,782,894,667 +$130,817,775 $179.41 406
2021 Q4 42,624,899 $9,209,865,142 -$255,129,444 $216.08 402
2021 Q3 43,517,178 $8,034,813,542 +$130,663,883 $184.58 409
2021 Q2 43,004,578 $7,714,135,399 +$18,696,460 $179.41 392
2021 Q1 42,199,091 $7,067,167,772 +$72,145,525 $167.27 380
2020 Q4 42,985,011 $6,525,391,483 +$195,664,438 $151.79 343
2020 Q3 41,458,638 $4,187,802,157 -$27,033,050 $101.00 314
2020 Q2 42,022,264 $5,083,365,436 -$62,885,303 $121.00 334
2020 Q1 42,317,827 $4,013,539,579 +$196,965,676 $94.83 288
2019 Q4 41,135,969 $3,622,553,098 -$14,393,169 $88.08 306
2019 Q3 40,479,716 $3,228,589,335 -$39,981,091 $79.75 286
2019 Q2 40,943,391 $3,194,308,708 -$110,413,587 $78.06 305
2019 Q1 42,668,638 $4,998,201,432 -$6,687,143 $117.37 361
2018 Q4 42,772,375 $4,644,656,939 -$44,680,615 $108.90 347
2018 Q3 42,400,368 $5,409,715,993 +$116,850,466 $127.88 354
2018 Q2 42,138,678 $4,757,224,858 -$111,489,973 $113.15 360
2018 Q1 43,327,389 $4,853,795,543 +$10,748,046 $112.36 361
2017 Q4 43,129,774 $6,361,909,413 +$197,931 $147.95 391
2017 Q3 43,659,867 $5,124,723,578 -$332,051,305 $117.19 364
2017 Q2 46,264,852 $6,004,918,581 -$218,808,511 $129.73 367
2017 Q1 47,725,280 $6,461,585,910 +$610,808,906 $135.38 401
2016 Q4 46,844,613 $6,713,728,830 -$108,523,542 $143.43 393
2016 Q3 48,590,495 $5,734,932,105 -$90,470,103 $118.08 383
2016 Q2 49,313,016 $5,224,505,518 -$125,744,632 $105.92 372
2016 Q1 50,640,999 $5,643,804,733 -$78,575,975 $111.43 390
2015 Q4 49,748,458 $7,792,616,829 -$12,044,878 $156.61 372
2015 Q3 49,983,276 $6,560,104,627 -$69,193,348 $131.24 360
2015 Q2 50,377,944 $8,762,290,786 -$264,447,068 $173.95 378
2015 Q1 52,358,250 $9,021,227,777 +$258,694,966 $172.43 365
2014 Q4 50,481,729 $6,541,552,799 -$247,055,871 $129.49 328
2014 Q3 52,842,225 $6,798,751,692 +$110,623,345 $128.65 318
2014 Q2 52,197,884 $4,620,244,446 -$1,253,814,742 $88.49 303
2014 Q1 53,381,219 $5,019,682,084 -$140,614,405 $94.03 303